论文部分内容阅读
目的:总结中山大学肿瘤防治中心泌尿外科过去近10年间晚期睾丸非精原生殖细胞肿瘤(NSGCT)综合治疗临床疗效,对比分析临床晚期NSGCT不同治疗方案疗效与化疗疗程的关系。方法:回顾分析1999~2008年近10年间在中山大学肿瘤防治中心泌尿外科治疗的所有晚期NSGCT患者的临床资料。描述分析临床晚期NSGCT综合治疗临床疗效,比较分析是否行腹膜后淋巴结清扫术(RPLND)的患者3程以上BEP方案化疗与3程及以下化疗疗效的差异,统计学方法采用Kaplan-Meier。结果:RPLND术后行BEP方案≤3程与>3程化疗预后的差异无统计学意义(P=0.623)。未行RPLND的患者>3程化疗预后优于≤3程化疗(P=0.021)。结论:Ⅱ/Ⅲ期NSGCT化疗前接受RPLND可减少化疗疗程从而减轻化疗不良反应。
OBJECTIVE: To summarize the clinical efficacy of comprehensive treatment of advanced testicular non-spermatogenetic germ cell tumors (NSGCT) in the Department of Urology, Sun Yat-sen University Cancer Center, and to analyze the relationship between the efficacy of different NSGCT regimens and chemotherapy regimens. Methods: The clinical data of all patients with advanced NSGCT treated with urology at Sun Yat - sen University Cancer Center in 1999 and 2008 were reviewed retrospectively. Describes the analysis of clinical clinical efficacy of NSGCT late clinical treatment, comparative analysis of patients undergoing retroperitoneal lymph node dissection (RPLND) more than three courses of chemotherapy and BEP three courses and the following chemotherapy, Kaplan-Meier statistical methods. Results: There was no significant difference in prognosis between RPLND BEP regimen ≤ 3 courses and> 3 courses (P = 0.623). Patients who did not undergo RPLND had a> 3-course chemotherapy benefit over ≤3-course chemotherapy (P = 0.021). Conclusion: RPLND can reduce the duration of chemotherapy before Ⅱ / Ⅲ NSGCT chemotherapy and thus reduce the adverse reactions of chemotherapy.